"fits with the high growth, high multiple acquisitions selected by management. While near-term dilution of a few pennies and the premium valuation are not positives, we believe the announcement removes the acquisition overhang for the stock, and long-term accretion and growth are a positive."According to publicly available sources Qiagen NV (QIA) has 232.83M shares which, at $20 is $4.656B and at $24 is $5.578B. If you were to accept the valuation of Peter Lawson of Mizuho Securities the purchase of Cellestis, for $341.3M will improve the value of QIA by $931.2M!
Lawson raised the 12-month target on Qiagen's shareprice to $24 from $20
Now I know that there is always a margin between wholesale and retail but 270%....
(For the exercise I have assumed parity for the $AU)
HT: puzzled
